Amarnath Natarajan

This study identifies mTOR signaling as a therapeutic target in AXL-deficient advanced prostate cancer through kinase inhibitor screening and functional analysis.

This paper develops BTE-EN1, a compound that inhibits prostate cancer-mediated bone destruction by targeting cell motility and osteoclast activity, showing efficacy in mice.

This study investigates the role of Tyr34 in MnSOD catalysis using neutron diffraction, X-ray spectroscopy, and quantum chemistry calculations, revealing its impact on proton-coupled electron transfer.

The paper identifies a potent MET degrader using live cell imaging, showing it is more effective than existing PROTACs.

The paper identifies FBXO21 as a therapeutic target in AML by developing a small molecule that inhibits p85 ubiquitination, reducing PI3K pathway activity and inducing cell death.

The paper uses protein 3D structure analysis to discover novel anticancer compounds by targeting unique structural motifs, identifying Dxr2-017 as a selective inhibitor of melanoma cells.

This paper evaluates SpiD3, a novel spirocyclic dimer, showing potent anti-leukemic effects in CLL cells, including resistance to ibrutinib, by targeting NF-κB signaling and the UPR.

This study develops a rodent model of rotational head trauma, identifies Cdk5 as a key mediator, and shows its inhibition reduces cognitive and pathological effects.